Maribavir

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Maribavir is an orally bioavailable benzimidazole l-riboside antiviral drug, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein-Barr virus (EBV). It is a potent and specific inhibitor of the CMV UL97 kinase. Maribavir is the generic name for 5,6-dichloro-2- (isopropylamino)-1-beta-l-ribofuranosylbenzimidazole, with the chemical structure as shown in Figure 223.1. The molecular weight is 376.24. Investigational drug code names include (BW)1263W94, GW257406X, VP41263, and SHP620 reflecting sequential changes in corporate ownership. Over the past 20 years, maribavir has undergone various clinical trials as an experimental CMV antiviral drug. Earlier phase I and II trials showed anti-CMV activity with an acceptable adverse effect profile. Unsuccessful phase III trials of low-dose maribavir for prevention of CMV infection in transplant patient populations ended in 2009, followed a few years later by phase II CMV treatment trials at higher doses, which were announced as successful in 2015. There is continued clinical interest in this compound because of its distinct antiviral target, oral bioavailability and favorable toxicity profile, although its optimal therapeutic role remains to be determined.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Pages3640-3646
Number of pages7
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
DOIs
StatePublished - Jan 1 2017

Fingerprint

Cytomegalovirus
Antiviral Agents
Names
Investigational Drugs
Ownership
Cytomegalovirus Infections
Human Herpesvirus 4
Biological Availability
maribavir
Phosphotransferases
Molecular Weight
Clinical Trials
Transplants
Therapeutics
Population

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Chou, S. (2017). Maribavir. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition (pp. 3640-3646). CRC Press. https://doi.org/10.1201/9781315152110

Maribavir. / Chou, Sunwen.

Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. p. 3640-3646.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chou, S 2017, Maribavir. in Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, pp. 3640-3646. https://doi.org/10.1201/9781315152110
Chou S. Maribavir. In Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press. 2017. p. 3640-3646 https://doi.org/10.1201/9781315152110
Chou, Sunwen. / Maribavir. Kucers the Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition. CRC Press, 2017. pp. 3640-3646
@inbook{ca851481ca17427b9b9bba50f0932bea,
title = "Maribavir",
abstract = "Maribavir is an orally bioavailable benzimidazole l-riboside antiviral drug, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein-Barr virus (EBV). It is a potent and specific inhibitor of the CMV UL97 kinase. Maribavir is the generic name for 5,6-dichloro-2- (isopropylamino)-1-beta-l-ribofuranosylbenzimidazole, with the chemical structure as shown in Figure 223.1. The molecular weight is 376.24. Investigational drug code names include (BW)1263W94, GW257406X, VP41263, and SHP620 reflecting sequential changes in corporate ownership. Over the past 20 years, maribavir has undergone various clinical trials as an experimental CMV antiviral drug. Earlier phase I and II trials showed anti-CMV activity with an acceptable adverse effect profile. Unsuccessful phase III trials of low-dose maribavir for prevention of CMV infection in transplant patient populations ended in 2009, followed a few years later by phase II CMV treatment trials at higher doses, which were announced as successful in 2015. There is continued clinical interest in this compound because of its distinct antiviral target, oral bioavailability and favorable toxicity profile, although its optimal therapeutic role remains to be determined.",
author = "Sunwen Chou",
year = "2017",
month = "1",
day = "1",
doi = "10.1201/9781315152110",
language = "English (US)",
isbn = "9781498747950",
pages = "3640--3646",
booktitle = "Kucers the Use of Antibiotics",
publisher = "CRC Press",

}

TY - CHAP

T1 - Maribavir

AU - Chou, Sunwen

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Maribavir is an orally bioavailable benzimidazole l-riboside antiviral drug, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein-Barr virus (EBV). It is a potent and specific inhibitor of the CMV UL97 kinase. Maribavir is the generic name for 5,6-dichloro-2- (isopropylamino)-1-beta-l-ribofuranosylbenzimidazole, with the chemical structure as shown in Figure 223.1. The molecular weight is 376.24. Investigational drug code names include (BW)1263W94, GW257406X, VP41263, and SHP620 reflecting sequential changes in corporate ownership. Over the past 20 years, maribavir has undergone various clinical trials as an experimental CMV antiviral drug. Earlier phase I and II trials showed anti-CMV activity with an acceptable adverse effect profile. Unsuccessful phase III trials of low-dose maribavir for prevention of CMV infection in transplant patient populations ended in 2009, followed a few years later by phase II CMV treatment trials at higher doses, which were announced as successful in 2015. There is continued clinical interest in this compound because of its distinct antiviral target, oral bioavailability and favorable toxicity profile, although its optimal therapeutic role remains to be determined.

AB - Maribavir is an orally bioavailable benzimidazole l-riboside antiviral drug, with a spectrum of activity essentially limited to human cytomegalovirus (CMV) and Epstein-Barr virus (EBV). It is a potent and specific inhibitor of the CMV UL97 kinase. Maribavir is the generic name for 5,6-dichloro-2- (isopropylamino)-1-beta-l-ribofuranosylbenzimidazole, with the chemical structure as shown in Figure 223.1. The molecular weight is 376.24. Investigational drug code names include (BW)1263W94, GW257406X, VP41263, and SHP620 reflecting sequential changes in corporate ownership. Over the past 20 years, maribavir has undergone various clinical trials as an experimental CMV antiviral drug. Earlier phase I and II trials showed anti-CMV activity with an acceptable adverse effect profile. Unsuccessful phase III trials of low-dose maribavir for prevention of CMV infection in transplant patient populations ended in 2009, followed a few years later by phase II CMV treatment trials at higher doses, which were announced as successful in 2015. There is continued clinical interest in this compound because of its distinct antiviral target, oral bioavailability and favorable toxicity profile, although its optimal therapeutic role remains to be determined.

UR - http://www.scopus.com/inward/record.url?scp=85056675185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056675185&partnerID=8YFLogxK

U2 - 10.1201/9781315152110

DO - 10.1201/9781315152110

M3 - Chapter

SN - 9781498747950

SP - 3640

EP - 3646

BT - Kucers the Use of Antibiotics

PB - CRC Press

ER -